Key Highlights
- OptimizeRx shares are trading down 15.53% at $7.56 versus a prior close of $8.95.
- Third quarter Revenue fell 17% to $21.6 million but beat consensus.
- Adjusted EBITDA rose to $6.3 million, a Margin of about 29% versus 20% a year ago.
- Full-year 2026 revenue guidance was cut to $87 million to $93 million from $95 million to $100 million.
- B. Riley trimmed its target to $10.50 from $11 and kept a Buy rating.
OptimizeRx (NASDAQ:OPRX) is trading down 15.53% at $7.56 after management lowered its 2026 revenue outlook, even as profit beat. Third quarter revenue of $21.6 million fell 17% from $26.1 million a year ago but topped consensus. Peer CareCloud (NASDAQ:CCLD) is trading up 1.70%, so the decline is specific to OptimizeRx.
Profit Improves as Revenue Shrinks
Adjusted EBITDA rose to $6.3 million from $5.1 million, lifting the margin to about 29% from about 20%. GAAP Net Income was $1.2 million, or $0.06 per share, and non-GAAP net income was $3.8 million, or $0.20 per diluted share. Expenses fell $5.1 million to $18.9 million after cost cuts earlier this year.
Management said the revenue decline came from reduced spending at a limited number of large customers, including users of a lower-margin managed services offering, plus budget pressure tied to most-favored-nation pricing uncertainty.
Guidance Cut Drives the Selloff
Full-year 2026 revenue guidance now sits at $87 million to $93 million, down from $95 million to $100 million. Adjusted EBITDA guidance of $21 million to $25 million was maintained, with gross margin expected in the low 70% range.
Contracted revenue is still tracking about 20% below last year, and a little over 90% of the midpoint is contracted, versus the mid-90% range in prior years. Fourth quarter results depend on customer spending decisions management cannot yet see.
Retention Slips, but 2027 Looks Stronger
Net revenue retention fell to 83%. Management tied about 10 points of that to one displaced top five client, which has resumed spending in the fourth quarter at levels below history. A few large accounts also trimmed spending.
Early 2027 looks better. Contracted revenue is about 20% ahead of last year, and management sees no major revenue gaps next year, though it gave no 2027 guidance. Integrations with The Trade Desk, Deep Intent and PulsePoint cover an estimated 60% to 70% of the programmatic market, though revenue from them is still early. PulsePoint will add about 250,000 provider identifiers, with inventory available through November.
Balance Sheet and Leadership
Cash was $22.3 million, and Debt fell to $13.4 million at quarter end and $10.4 million after a further $3 million paydown. Management signaled more share repurchases in the fourth quarter and expects margins to scale toward 30% or more as revenue grows. Chief Financial Officer Ed Stelmakh departs at year-end, and Sarah Bast joined as Chief Marketing Officer during the quarter.
Fourth Quarter Conversion Decides the Rebound
The question is whether OptimizeRx can book enough in the fourth quarter to land inside the new range. Seven analysts cover the stock, with six bullish and an average target of $13.07, far above $7.56. B. Riley cut its target to $10.50 from $11 and kept Buy.
Next markers are the pace of December bookings, how fast the programmatic integrations add revenue, the CFO handover and 2027 guidance.






Please wait processing your request...